Abstracts tagged "autoimmune diseases"

Abstract Number: 0366 • ACR Convergence 2025
Dental Findings in Patients With Rheumatic Diseases and Its Association With Self-Perceived Oral Health
Fernanda M. Garcia-Garcia¹, Margarita Isabel Alarcon-Jarquin², Vanessa L. Lopez-Flores², Gabriel P. Castro-Cruz³, Carlos I. Estrada-Anguiano³, Jennifer Garcia-Bravo³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado¹ and Janett C. Riega-Torres⁴, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health conditions are frequent in patients with rheumatic diseases and can impact daily function and quality of life. Factors such as chronic inflammation…
Abstract Number: 0270 • ACR Convergence 2025
Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria
Rafael Gálvez Sánchez¹, Ivan Ferraz Amaro², Fernando Lopez Gutierrez³, Javier Loricera⁴, Pablo Martínez Calabuig⁵, Jorge Juan Fragío Gil⁶, Roxana González Mazarí⁷, Cristina Hormigos Martín⁸, DALIFER FREITES⁹, Maria Rodríguez Laguna⁸, Patricia Moya Alvarado¹⁰, Marta López I Gómez¹¹, Hector Corominas Macia¹⁰, Maite Silva Díaz¹², Guillermo González Arribas¹², Angel García Aparicio¹³, Judit Font-Urgelles¹⁴, Ivette Casafont Solé¹⁵, Elisabet Castaneda¹⁶, Carolina Merino Argumánez¹⁷, Raquel Zas Vaamonde¹⁸, Juan Molina Collada¹⁹, Sergio Rodríguez Montero²⁰, Rafael Melero Gonzalez²¹, Eva Galíndez Agirregoikoa²², Andrea Hernández²³, Lucia Pantoja Zarza²⁴, Ignacio Braña Abascal²⁵, Vega Jovaní²⁶, Elia Valls Pascual²⁷, Natalia Mena Vázquez²⁸, ADELA MARIA GALLEGO FLORES²⁹, Noelia Cabaleiro Raña³⁰, Raúl Veroz González³¹, Mariano Andrés³², Santos Castañeda Sainz³³ and Ricardo Blanco³⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁶Hospital General Universitario, Valencia, Spain, ⁷Hospital General Universitario de Valencia, Reumatología, Valencia, Valencia, Spain, ⁸Hospital Clínico San Carlos, Reumatología, Madrid, Madrid, Spain, ⁹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Reumatología, Barcelona, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Reumatología, Vitoria,, Vitoria, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, Reumatología, A Coruña, Spain, ¹³Hospital Universitario de Toledo, Reumatología, Toledo, Toledo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital German Trias i Pujol, Reumatología, Badalona, Badalona, Spain, ¹⁶Hospital Universitario Infanta Sofía, Reumatología, Madrid, Madrid, Spain, ¹⁷Hospital Universitario Puerta del Hierro, Reumatología, Madrid, Madrid, Spain, ¹⁸Hospital Universitario ¹² de Octubre, Reumatología, Madrid, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Reumatología, Madrid, Madrid, Spain, ²⁰Hospital Universitario de Valme, Reumatología, Sevilla, Sevilla, Spain, ²¹Hospital Alvaro Cunqueiro, Reumatología, Vigo, Vigo, Spain, ²²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²³Hospital Universitario de Gran Canaria Dr Negrin, Reumatología, Palmas de Gran Canaria, Gran Canaria, Spain, ²⁴Hospital General de Segovia, Reumatología, Segovia, Segovia, Spain, ²⁵Hospital Universitario Central de Asturias, Reumatología, Oviedo, Oviedo, Spain, ²⁶Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁷Hospital General de Valencia, Reumatología, Valencia, Valencia, Spain, ²⁸Hospital Regional Universitario de Málaga, Reumatología, Málaga, Malaga, Spain, ²⁹Complejo Hospitalario don Benito Villanueva, Reumatología, Badajoz, Badajoz, Extremadura, Spain, ³⁰Hospital Universitario Montecelo, Reumatología, Pontevedra, Pontevedra, Spain, ³¹Hospital de Mérida, Reumatología, Mérida, Mérida, Spain, ³²Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Spain, ³³Hospital Universitario La Princesa, Reumatología, Madrid Grupo de cooperación nacional de enfermedad relacionada con IgG⁴: Blanca García Magallón (Hospital Universitario Puerta del Hierro), Maite Odriozola Gil (Hospital Universitario de Valme), Cristina Arciniega (Hospital de Mérida), Maria Lourdes Mateo Soria (Hospital German Trias i Pujol), Santiago Muñoz (Hospital Universitario Infanta Sofía), Iñigo Jesús Rua Figueroa, (Hospital Universitario de Gran Canaria Dr Negrin), Sabela Fernández Aguado, (Hospital de Montecelo)., Madrid, Spain, ³⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by fibro-sclerosing inflammation, elevated serum and tissue IgG4 levels, and heterogeneous clinical manifestations. Several classification…
Abstract Number: 0208 • ACR Convergence 2025
Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Xu Wang, Lifan Zhang and Lidan Zhao, Peking Union Medical College Hospital, Beijing, China (People's Republic)
Background/Purpose: This study aimed to assess the current clinical practices of tuberculosis (TB) infection screening and TB preventive treatment (TPT) among patients with rheumatic diseases,…
Abstract Number: 0082 • ACR Convergence 2025
IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model
Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
Abstract Number: 0010 • ACR Convergence 2025
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Matthew Bernett¹, Gregory Moore², Katrina Bykova², Viralkumar Davra², Seung Chu², Michael Sheard², Ruschelle Love², Norman Barlow², Engie Salama², Jitendra Kanodia², Panida Lertkiatmongkol², Dipankar Chaudhuri², Kendra Avery², Hanh Nguyen², Rumana Rashid², Ke Liu², Jing Qi², Araz Eivazi², Thuy Truong², Sher Karki², James Ernst², Rena Bahjat² and John Desjarlais², ¹Xencor, Inc., Pasadena, CA, ²Xencor, Inc., Pasadena
Background/Purpose: B cell depletion is a validated therapeutic strategy in autoimmune disease, but current approaches targeting CD20 may only partially eliminate disease-driving subsets such as…
Abstract Number: 2701 • ACR Convergence 2025
Ophthalmic Manifestations of Relapsing Polychondritis
Akash Gupta¹, Rennie Rhee², Kaitlin Quinn³, Naomi Amudala², Nirali Bhatt⁴, Carol McAlear², Marcela ferrada⁵, Peter Grayson⁶, Peter Merkel² and Shubhasree Banerjee², ¹Hospital of University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, ⁵University of Maryland, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: The prevalence of ocular involvement (OI) in patients with relapsing polychondritis (RP) has not been well defined. This study aimed to describe ocular manifestations,…
Abstract Number: 2581 • ACR Convergence 2025
From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus
Angelique Cortez¹, Lindsay Mendyka², Paola Garcia³, Elizabeth Nowak¹, Fred Kolling⁴, Lucas Salas¹, Christopher Burns⁵, Andrea Fava⁶ and Sladjana Skopelja-Gardner⁷, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Lyme, NH, ³St. Mary's University, San Antonio, TX, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Health, Lebanon, NH, ⁶Johns Hopkins University, Baltimore, MD, ⁷Dartmouth Geisel School of Medicine, Lebanon, NH
Background/Purpose: The majority of SLE patients are sensitive to ultraviolet light (UV), which can lead to local and systemic inflammation, including lupus nephritis (LN) flares.…
Abstract Number: 2466 • ACR Convergence 2025
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Richard Furie¹, Neel Anand², Shraddha Desai³, Eric Lowe⁴, Tony Muchamuel³, Kiruthi Palaniswamy², Rachel Peterson², Kathryn Ray², Zung To², Jennifer Whang² and Richard Leff⁵, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Kezar Life Sciences, Inc, South San Francisco, CA, ³Kezar Life Sciences, Inc, South San Francisco, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Richard L Leff MD LLC, Chadds Ford, PA
Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
Abstract Number: 2329 • ACR Convergence 2025
Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
Sehneet Grewal, Rubab Rizwan, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, Poughkeepsie, NY
Background/Purpose: Psoriasis, a chronic inflammatory skin condition, is increasingly linked to systemic cardiovascular risks. Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with…
Abstract Number: 2018 • ACR Convergence 2025
Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study
Archit Srivastava¹, Jayesh Valecha², Sehreen Mumtaz¹, Caroyln Harvey³, Florentina Berianu¹ and Vikas Majithia⁴, ¹Mayo Clinic Florida, Jacksonville, FL, ²Saint Vincent Hospital, Worchester, FL, ³Mayo Clinic, Phoenix, AZ, ⁴Mayo Clinic Hospital, Jacksonville, FL
Background/Purpose: Uveitis is a significant cause of visual impairment in the U.S., with a prevalence of 438 per 100,000 persons [1]. It is anatomically classified…
Abstract Number: 1799 • ACR Convergence 2025
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
Xiao-Na Ma¹, Mei-Feng Shi¹, Qian Chen¹, Fang-Shu Zou¹, Wei Feng¹, Qing-Ping Liu¹, Chang-Song Lin¹, Nan Li², Xiao-Bao Liu¹ and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²School of Traditional Chinese Medicine, Jinan University, Guangzhou, China (People's Republic)
Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…
Abstract Number: 1666 • ACR Convergence 2025
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
John Stone¹, Mollie Carruthers², Alireza Meysami³, Matthew Charles Baker⁴, Daniela Ghetie⁵, Lindsay Lally⁶, Fernando Martinez-Valle⁷, Lorenzo Dagna⁸, nicolas schleinitz⁹, Jeea Choi¹⁰, Leda Mannent¹¹ and Owen Hagino¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Henry Ford Health, Detroit, MI, ⁴Stanford University, Menlo Park, CA, ⁵Oregon Health and Science University, Portland, OR, ⁶Hospital for Special Surgery, NEW YORK, NY, ⁷Vall d’Hebron Hospital, Barcelona, Spain, ⁸IIRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Sanofi, Morristown, NJ, ¹¹Sanofi, Gentilly, France
Background/Purpose: IgG4-RD is a progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is a reversible, orally available inhibitor of Bruton's tyrosine kinase (BTKi). Here,…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1378 • ACR Convergence 2025
Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
Arun Varadhachary¹, Ghaith Noaiseh², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹Washington University in St. Louis, St. Louis, MO, ²University of Kansas Medical Center, Kansas City, KS, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is a systemic autoimmune disorder with diverse clinical manifestations affecting multiple organ systems. While dry mouth, dry eyes, fatigue and pain are…
Abstract Number: 1178 • ACR Convergence 2025
An International modified Delphi Study on the evolving role of Janus kinase inhibitors (JAKi) in rheumatic and musculoskeletal diseases (RMDs)
Anna Barkaway¹, Philip J. Mease², Zoe Rutter-Locher³, Robert Moots⁴, Mwidimi Ndosi⁵ and Michael McLean⁶, ¹Pfizer UK, Tadworth, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Guys and St Thomas NHS trust, London, United Kingdom, ⁴Liverpool University Hospitals, Liverpool, United Kingdom, ⁵University of the West of England, Bristol, Filton, United Kingdom, ⁶Pfizer, Glasgow, United Kingdom
Background/Purpose: The development of advanced therapies such as JAK inhibitors (JAKi) has expanded treatment options available for patients with rheumatic and musculoskeletal diseases (RMDs). Case…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].